bs-20730R **[Primary Antibody]**

DRD2 Rabbit pAb

www.bioss.com.cn
sales@bioss.com.cn
techsupport@bioss.com.cn
400-901-9800

DATASHEET

Host: Rabbit **Isotype:** IgG

Clonality: Polyclonal

GeneID: 1813 **SWISS:** P14416

Target: DRD2

Immunogen: KLH conjugated synthetic peptide derived from human DRD2: 301-400/443.

Purification: affinity purified by Protein A

Concentration: 1mg/ml

Storage: 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Background: This gene encodes the D2 subtype of the dopamine receptor. This G-protein coupled receptor inhibits adenylyl cyclase activity. A missense mutation in this gene causes myoclonus dystonia; other mutations have been associated with schizophrenia. Alternative splicing of this gene results in two transcript variants encoding different isoforms. A third variant has been described, but it has not been determined whether this form is normal or due to aberrant splicing. [provided by RefSeq, Jul 2008]

Applications: **WB** (1:500-2000)
ELISA (1:5000-10000)

Reactivity: Human, Mouse, Rat (predicted: Rabbit, Sheep, Cow, Dog, Horse)

Predicted MW.: 51 kDa

Subcellular Location: Cell membrane ,Cytoplasm

VALIDATION IMAGES



25 ug total protein per lane of various lysates (see on figure) probed with DRD2 polyclonal antibody, unconjugated (bs-20730R) at 1:1000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at r.t. for 60 min.

SELECTED CITATIONS

- **[IF=9.8]** Xiaoyan Zheng. et al. Novel findings from arsenic-lead combined exposure in mouse testicular TM4 Sertoli cells based on transcriptomics. SCI TOTAL ENVIRON. 2023 Dec;:169611 WB ;Mouse. 38157908
- **[IF=4.01]** Wang YH et al. Isosibiricin inhibits microglial activation by targeting the dopamine D1/D2 receptor-dependent NLRP3/caspase-1 inflammasome pathway. Acta Pharmacol Sin. 2019 Sep 10. WB,IHC ;Mouse. 31506572
- **[IF=2.751]** Xuezhi Zhang. et al. Natural emodin reduces myocardial ischemia/reperfusion injury by modulating the RUNX1/miR-142-3p/DRD2 pathway and attenuating inflammation. EXP THER MED. 2022 Dec;24(6):1-11 WB ;Mouse. 10.3892/etm.2022.11681